ICYMI: Biogen, GSK And Roche Slip Pipeline Setbacks Into Earnings Reports
Executive Summary
The first round of third-quarter earnings reports for big pharmas quietly featured news about drug discontinuations and failures.
You may also be interested in...
Deal Watch: Lilly Partners With Avidity On RNA Medicines That Can Target Outside The Liver
Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.
Roche's Post-Avastin Strategy Stumbles As Vanucizumab Fails In Phase II
Roche's development plans for a follow-on Avastin product have been called into question after the company noted briefly in its third-quarter earnings update that the drug failed in a Phase II study in colorectal cancer patients.
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next
GlaxoSmithKline’s HIV-focused business unit is growing leaps and bounds, while the company’s other pharmaceutical sales slump. ViiV CEO Dominique Limet talked in an interview about the increased pressure success brings and how ViiV intends to keep delivering.